Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel

被引：0
|
作者：
Ya-nan Man
Yan-fang Chen
机构：
[1] The Second Hospital of Tianjin Medical University,Department of Radiation Oncology
来源：
International Urology and Nephrology | 2019年 / 51卷
关键词：
SII; -dimer; Fibrinogen; CRPC; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2189 / 2199
页数：10
相关论文
共 50 条
  • [41] Serum testosterone level and overall survival in first-line abiraterone and enzalutamide for metastatic castration-resistant prostate cancer patients.
    Silveira Vilbert, Maysa Tamara
    Cesca, Marcelle Goldner
    Pandolfi, Natasha Carvalho
    Calsavara, Vinicius Fernando
    de Mendonca Uchoa, Bruno Cezar
    de Andrade, Poliana
    Coelho, Ricardo Lima
    Corassa, Marcelo
    Rinck, Jose A.
    Dettino, Aldo A.
    Oliveira, Thiago Bueno
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.
    Gross-Goupil, Marine
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Pierres, Marie
    Capone, Camille
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] IMPACT OF C-REACTIVE PROTEIN KINETICS ON SURVIVAL OF CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH DOCETAXEL
    Saito, K.
    Ito, M.
    Kijima, T.
    Numao, N.
    Koga, F.
    Masuda, H.
    Fujii, Y.
    Kawakami, S.
    Urakami, S.
    Yuasa, T.
    Yamamoto, S.
    Yonese, J.
    Fukui, I
    Kihara, K.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 336 - 337
  • [44] Association of body composition with survival and efficacy of first-line treatment in patients with castration-resistant prostate cancer
    Joung, Jae Young
    Pak, Sahyun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [45] Impact of body composition parameters on clinical outcomes in patients with metastatic castration-resistant prostate cancer treated with docetaxel
    Power, Derek Gerard
    Cushen, Samantha
    McDermott, Ray
    Lim, Marvin Chang Jui
    Mceneaney, Peter
    Daly, Louise
    Griffin, Brendan
    Murphy, Kevin P.
    Ryan, Aoife M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel
    Nuhn, Philipp
    Vaghasia, Ajay M.
    Goyal, Jatinder
    Zhou, Xian C.
    Carducci, Michael A.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    BJU INTERNATIONAL, 2014, 114 (6B) : E11 - E17
  • [47] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
    Caffo, Orazio
    Ortega, Cinzia
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Facchini, Gaetano
    Veccia, Antonello
    Palesandro, Erica
    Verri, Elena
    Buti, Sebastiano
    Razzini, Giorgia
    Bozza, Giovanni
    Maruzzo, Marco
    Ciccarese, Chiara
    Schepisi, Giuseppe
    Rossetti, Sabrina
    Maines, Francesca
    Kinspergher, Stefania
    Fratino, Lucia
    Ermacora, Paola
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Sabbatini, Roberto
    Lo Re, Giovanni
    Morelli, Franco
    D'Angelo, Alessandro
    Vittimberga, Isabella
    Lippe, Paolo
    Carrozza, Francesco
    Messina, Caterina
    Galli, Luca
    Valcamonico, Francesca
    Porta, Camillo
    Pappagallo, Giovanni
    Aglietta, Massimo
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
  • [48] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [49] The Effect of Therapeutic Anticoagulation on Overall Survival in Men Receiving First-Line Docetaxel Chemotherapy for Metastatic Castration-Resistant Prostate Cancer
    Park, Jong Chul
    Pratz, Caroline F.
    Tesfaye, Anteneh
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (01) : 32 - 38
  • [50] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
    Wu, Kai-Jie
    Pei, Xin-Qi
    Tian, Ge
    Wu, Da-Peng
    Fan, Jin-Hai
    Jiang, Yu-Mei
    He, Da-Lin
    ASIAN JOURNAL OF ANDROLOGY, 2018, 20 (02) : 173 - 177
12345